SCHEMBL2651839

SCHEMBL2651839

COCC#Cc1ccc(C(CC2CCCC2)C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
ACACB O00763 1/20 0.35
AGTR2 P50052 3/20 0.35
FFAR1 O14842 1/20 0.34
GCK P35557 3/20 0.34
APP P05067 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
GPR88 Q9GZN0 1/20 0.34
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2650114 0.89 CYP2D6 (0.42) CYP2D6CYP2C19MMP2MMP9MMP12
SCHEMBL2650870 0.85 MMP2 (0.44) MMP2MMP9MMP12ACACBAGTR2
SCHEMBL2651218 0.83 ALDH1A1 (0.45) CYP2C19MMP2MMP9MMP12AGTR2
SCHEMBL2653001 0.83 MMP2 (0.41) MMP2MMP9MMP12ACACBFFAR1
SCHEMBL2651907 0.78 MMP2 (0.39) MMP2MMP9MMP12ACACBGCK
SCHEMBL2650617 0.78 GCK (0.65) CYP2D6CYP2C19CYP3A4CYP2C9GCK
SCHEMBL2652113 0.78 MEN1 (0.44) MMP2MMP9MMP12AGTR2
SCHEMBL2645029 0.78 TSHR (0.41) MMP2MMP9MMP12FFAR1
SCHEMBL2651230 0.78 MMP2 (0.41) MMP2MMP9MMP12FFAR1GCK
SCHEMBL2646192 0.78 EPHX2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1282612-B1 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
EP-1282612-A2 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-12 EP disclosed
US-6388071-B2 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-05-14 US disclosed
US-20010053851-A1 Alkynyl phenyl heteroaromatic glucokinase activators HOFFMAN-LA ROCHE INC. 2001-12-20 US disclosed
WO-2001083465-A2 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053851-A1 Alkynyl phenyl heteroaromatic glucokinase activators GCK, GCKR, HK2 CYP2D6 940/4885CYP2C19 1467/4885MMP2 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.